BR112022025190A2 - Construtos de anellovirus em tandem - Google Patents

Construtos de anellovirus em tandem

Info

Publication number
BR112022025190A2
BR112022025190A2 BR112022025190A BR112022025190A BR112022025190A2 BR 112022025190 A2 BR112022025190 A2 BR 112022025190A2 BR 112022025190 A BR112022025190 A BR 112022025190A BR 112022025190 A BR112022025190 A BR 112022025190A BR 112022025190 A2 BR112022025190 A2 BR 112022025190A2
Authority
BR
Brazil
Prior art keywords
anellovirus
tandem
constructs
nucleic acid
acid construct
Prior art date
Application number
BR112022025190A
Other languages
English (en)
Portuguese (pt)
Inventor
Delagrave Simon
James Lebo Kevin
Maniklal Nawandar Dhananjay
Louis Timpona Joseph
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of BR112022025190A2 publication Critical patent/BR112022025190A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/00044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
BR112022025190A 2020-06-12 2021-06-11 Construtos de anellovirus em tandem BR112022025190A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038483P 2020-06-12 2020-06-12
US202163146963P 2021-02-08 2021-02-08
PCT/US2021/037091 WO2021252955A1 (en) 2020-06-12 2021-06-11 Tandem anellovirus constructs

Publications (1)

Publication Number Publication Date
BR112022025190A2 true BR112022025190A2 (pt) 2023-03-07

Family

ID=78845951

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025190A BR112022025190A2 (pt) 2020-06-12 2021-06-11 Construtos de anellovirus em tandem

Country Status (12)

Country Link
US (1) US20230348933A1 (https=)
EP (1) EP4165198A4 (https=)
JP (1) JP2023530278A (https=)
KR (1) KR20230036110A (https=)
CN (1) CN116075591A (https=)
AU (1) AU2021288320A1 (https=)
BR (1) BR112022025190A2 (https=)
CA (1) CA3186894A1 (https=)
IL (1) IL298978A (https=)
MX (1) MX2022015802A (https=)
TW (1) TW202223095A (https=)
WO (1) WO2021252955A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function
CN119331914A (zh) * 2024-10-17 2025-01-21 中科开浦生物科技(湖北)有限公司 一种指环病毒感染性克隆的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593189B1 (fr) * 1986-01-22 1989-10-20 Pasteur Institut Nouveau retrovirus susceptible de provoquer le sida, antigenes obtenus a partir de ce retrovirus et anticorps correspondants et leurs applications au diagnostic du sida
US9228242B2 (en) * 2009-08-21 2016-01-05 Virginia Tech Intellectual Properties, Inc. Porcine torque teno virus vaccines and diagnosis
WO2014204724A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
RU2744193C2 (ru) * 2015-10-16 2021-03-03 Канзас Стейт Юниверсити Рисерч Фаундейшн Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
IL271275B1 (en) * 2017-06-13 2026-04-01 Flagship Pioneering Innovations V Inc Preparations containing croons and their uses
CA3119814A1 (en) * 2018-12-12 2020-06-18 Flagship Pioneering Innovations V, Inc. Anellosomes for delivering protein replacement therapeutic modalities
MX2021006977A (es) * 2018-12-12 2021-10-13 Flagship Pioneering Innovations V Inc Anellosomas y metodos de uso.
CN114127302A (zh) * 2018-12-12 2022-03-01 旗舰先锋创新V股份有限公司 用于递送细胞内治疗方式的指环体

Also Published As

Publication number Publication date
CN116075591A (zh) 2023-05-05
CA3186894A1 (en) 2021-12-16
JP2023530278A (ja) 2023-07-14
IL298978A (en) 2023-02-01
US20230348933A1 (en) 2023-11-02
AU2021288320A1 (en) 2023-01-19
TW202223095A (zh) 2022-06-16
WO2021252955A1 (en) 2021-12-16
MX2022015802A (es) 2023-03-28
KR20230036110A (ko) 2023-03-14
EP4165198A1 (en) 2023-04-19
EP4165198A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
BR112022025190A2 (pt) Construtos de anellovirus em tandem
BR112022018854A2 (pt) Composições e métodos de rna circular
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
Gogrefe et al. Structure of a functional cap-binding domain in Rift Valley fever virus L protein
BR112022015628A2 (pt) Vacina de sars-cov-2
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
BR112022026127A2 (pt) Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
BR112019012183A2 (pt) métodos de modificar o material genético de uma célula eucariótica e de um organismo, vetor de expressão de polinucleotídeo, e, célula procariótica.
BR112018011059A2 (pt) synp161, um promotor para a expressão específica de genes em fotoreceptores de haste
BRPI0916355B8 (pt) Vetor recombinante compreendendo um polinucleotídeo isolado, e, método para produzir um precursor de piripiropeno a
BR112023002395A2 (pt) Sistema de baculovírus modificado para produção aprimorada de dna com extremidades fechadas (cedna)
BRPI1011144B8 (pt) proteína precursora, sequência de ácido nucleico, cassete de expressão, vetor recombinante, método para produzir um peptídeo desejado, e, uso de um peptídeo anfifílico
ECSP22050231A (es) Prote?nas gpcr de opsinas quim?ricas
BRPI0815392A8 (pt) Método para produzir planta de nicotiana tabacum transgênica com um teor de nitrito reduzido, uso de uma sequência de ácido nucleico exógeno, gene quimérico, e, vetor de transformação de planta
WO2022008510A3 (en) Intron-encoded extranuclear transcripts for protein translation, rna encoding, and multi-timepoint interrogation of non-coding or protein-coding rna regulation
AR065282A1 (es) Composiciones y metodos que utilizan arn de transferencia de genes tipo cad para el control de nematodos
MX2022015208A (es) Constructos de acido nucleico para fabricacion de proteinas.
CL2022001481A1 (es) Composiciones de ácidos nucleicos
BR112023026176A2 (pt) Vetores de expressão, vetores livres de sequência bacteriana e métodos de fabricação e uso dos mesmos
AR103921A1 (es) Moléculas de ácido nucleico de ii33 de arn polimerasa para el control de plagas de insectos
CO2022013638A2 (es) Enzimas para la sialilación de glicanos
BR112022022967A2 (pt) Processo de purificação de proteínas provenientes da clara do ovo de galinha e seu uso como agente antiviral contra sars-cov-2
BR112023001096A2 (pt) Métodos e composições para aumentar a imunidade contra coronavírus
WO2021202443A3 (en) Compositions and methods for silencing dnajc15 gene expression
UY40243A (es) Ácido nucleico aislado que codifica una proteína de fusión basada en fviii-bdd y en un péptido señal

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.